Ryoncil Revenues Increase 66% in Second Quarter Post Launch
Filed with ASX · · 2 pages · English
Earlier from Mesoblast
- Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
- Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
- Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
- Mesoblast Option to Issue up to US$50m Convertible Notes
- Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
Later from Mesoblast
- Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
- Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
- James M. O’Brien Appointed Chief Financial Officer at Mesoblast
- Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
- Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast